Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

Tactile Systems Technology, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MINNEAPOLIS, NOV. 03, 2025 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025 AND ANNOUNCED THE ADOPTION OF A SECOND SHARE REPURCHASE PROGRAM. THIRD QUARTER 2025 SUMMARY & RECENT BUSINESS HIGHLIGHTS: TOTAL REVENUE INCREASED 17% YEAR-OVER-YEAR TO $85.8 MILLION GROSS MARGIN OF 76% VERSUS 75% IN Q3 2024 NET INCOME OF $8.2 MILLION VERSUS $5.2 MILLION IN Q3 2024 ADJUSTED EBITDA OF $14.4 MILLION VERSUS $10.7 MILLION IN Q3 2024 ANNOUNCED SIX-MONTH DATA DEMONSTRATING SUSTAINED BENEFITS OF FLEXITOUCH PLUS AS A FIRST-LINE THERAPY IN TREATING LYMPHEDEMA IN HEAD AND NECK CANCER PATIENTS REPAID THE FULL OUTSTANDING PRINCIPAL BALANCE OF $24.0 MILLION UNDER THE COMPANY'S TERM LOAN AUTHORIZED A SECOND PROGRAM TO REPURCHASE UP TO $25.0 MILLION OF THE COMPANY'S COMMON STOCK TACTILE MEDICAL DELIVERED STRONG THIRD QUARTER RESULTS, REFLECTING CONTINUED PROGRESS ACROSS OUR BUSINESS TRANSFORMATION AND PRODUCT INNOVATION INITIATIVES, SAID SHERI DODD, CHIEF EXECUTIVE OFFICER OF TACTILE MEDICAL.

TACTILE SYSTEMS TECHNOLOGY, INC. REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

MINNEAPOLIS, OCT. 28, 2025 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF NEW SIX-MONTH CLINICAL DATA DURING THE LATE-BREAKING POSTER SESSION AT THE AMERICAN CONGRESS OF REHABILITATION MEDICINE (ACRM) 102ND ANNUAL FALL CONFERENCE DEMONSTRATING SUSTAINED CLINICAL BENEFITS OF FLEXITOUCH PLUS AS A FIRST-LINE THERAPY FOR TREATING PATIENTS WITH HEAD AND NECK CANCER-RELATED LYMPHEDEMA.

LANDMARK STUDY DEMONSTRATES SUSTAINED CLINICAL BENEFITS OF FLEXITOUCH PLUS AS FIRST-LINE THERAPY IN TREATING HEAD AND NECK CANCER-RELATED LYMPHEDEMA

MINNEAPOLIS, OCT. 20, 2025 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY ANNOUNCED THAT THIRD QUARTER OF FISCAL YEAR 2025 FINANCIAL RESULTS WILL BE RELEASED AFTER THE MARKET CLOSES ON MONDAY, NOVEMBER 3, 2025.

TACTILE MEDICAL TO RELEASE THIRD QUARTER OF FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 3, 2025

MINNEAPOLIS, AUG. 04, 2025 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025. SECOND QUARTER 2025 SUMMARY & RECENT BUSINESS HIGHLIGHTS: TOTAL REVENUE INCREASED 7.8% YEAR-OVER-YEAR TO $78.9 MILLION GROSS MARGIN OF 75% VERSUS 74% IN Q2 2024 NET INCOME OF $3.2 MILLION VERSUS $4.3 MILLION IN Q2 2024 ADJUSTED EBITDA OF $7.7 MILLION VERSUS $9.1 MILLION IN Q2 2024 ANNOUNCED THE PRESENTATION OF NEW DATA DEMONSTRATING SIGNIFICANT BENEFITS ASSOCIATED WITH USE OF FLEXITOUCH PLUS IN TREATING PATIENTS WITH HEAD AND NECK CANCER-RELATED LYMPHEDEMA REPURCHASED $16.5 MILLION OF STOCK TO COMPLETE THE COMPANY'S SHARE REPURCHASE PROGRAM WE DELIVERED STRONG FINANCIAL PERFORMANCE IN THE SECOND QUARTER, MARKED BY TOTAL REVENUE GROWTH OF NEARLY 8% YEAR-OVER-YEAR AND AHEAD OF OUR PREVIOUSLY STATED EXPECTATIONS, SAID SHERI DODD, CHIEF EXECUTIVE OFFICER OF TACTILE MEDICAL.

TACTILE SYSTEMS TECHNOLOGY, INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

MINNEAPOLIS, JULY 21, 2025 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY ANNOUNCED THAT SECOND QUARTER OF FISCAL YEAR 2025 FINANCIAL RESULTS WILL BE RELEASED AFTER THE MARKET CLOSES ONMONDAY, AUGUST 4, 2025.

TACTILE MEDICAL TO RELEASE SECOND QUARTER OF FISCAL YEAR 2025 FINANCIAL RESULTS ON AUGUST 4, 2025

ABSTRACT PRESENTED AT ASCO 2025 ANNUAL MEETING FEATURES TWO-MONTH DATA FROM THE LARGEST RANDOMIZED TRIAL EVER CONDUCTED AMONG HEAD AND NECK CANCER SURVIVORS ABSTRACT PRESENTED AT ASCO 2025 ANNUAL MEETING FEATURES TWO-MONTH DATA FROM THE LARGEST RANDOMIZED TRIAL EVER CONDUCTED AMONG HEAD AND NECK CANCER SURVIVORS

NEW DATA DEMONSTRATES SIGNIFICANT CLINICAL AND QUALITY-OF-LIFE BENEFITS OF FLEXITOUCH PLUS IN TREATING LYMPHEDEMA AMONG HEAD AND NECK CANCER SURVIVORS

MINNEAPOLIS, MAY 20, 2025 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY ANNOUNCED THAT MANAGEMENT WILL BE PARTICIPATING IN TWO UPCOMING INVESTOR CONFERENCES. TACTILE MEDICAL IS SCHEDULED TO PRESENT AT THE WILLIAM BLAIR 45TH ANNUAL GROWTH STOCK CONFERENCE IN CHICAGO ON TUESDAY, JUNE 3, 2025, AT 3:20 P.M. CST AND AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK ON WEDNESDAY, JUNE 4, 2025, AT 2:35 P.M. EST.

TACTILE MEDICAL TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN JUNE

MINNEAPOLIS, MAY 05, 2025 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025.

TACTILE SYSTEMS TECHNOLOGY, INC. REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

MINNEAPOLIS, APRIL 21, 2025 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY ANNOUNCED THAT FIRST QUARTER OF FISCAL YEAR 2025 FINANCIAL RESULTS WILL BE RELEASED AFTER THE MARKET CLOSES ONMONDAY, MAY 5, 2025.

TACTILE MEDICAL TO RELEASE FIRST QUARTER OF FISCAL YEAR 2025 FINANCIAL RESULTS ON MAY 5, 2025

MINNEAPOLIS, MARCH 05, 2025 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE OPPENHEIMER 35TH ANNUAL HEALTHCARE MEDTECH & SERVICES CONFERENCE, WHICH IS BEING VIRTUALLY HELD FROM MARCH 17TH  20TH. MANAGEMENT WILL PARTICIPATE IN A VIRTUAL PRESENTATION ON TUESDAY, MARCH 18TH AT 12:00 P.M. EASTERN TIME.

TACTILE MEDICAL TO PRESENT AT THE OPPENHEIMER 35TH ANNUAL HEALTHCARE MEDTECH & SERVICES CONFERENCE

MINNEAPOLIS, FEB. 18, 2025 (GLOBE NEWSWIRE) -- TACTILE SYSTEMS TECHNOLOGY, INC. (TACTILE MEDICAL; THE COMPANY) (NASDAQ: TCMD), A MEDICAL TECHNOLOGY COMPANY PROVIDING THERAPIES FOR PEOPLE WITH CHRONIC DISORDERS, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2024.

Tactile Systems Technology, Inc.

TCMD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Tactile Systems Technology, Inc.

TCMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TCMD